Skip to search formSkip to main contentSkip to account menu

rofecoxib

Known as: 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one, 4-[4'-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone, rofecoxib [Chemical/Ingredient] 
A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (3)

Cyclooxygenase 2 InhibitorsLactonesSulfones
Degenerative polyarthritisDrug AllergyDysmenorrheaNCIt Antineoplastic Agent Terminology

Narrower (3)

MK 0966Vioxxrefecoxib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury.
Highly Cited
2004
Highly Cited
2004
Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain
Highly Cited
2004
Highly Cited
2004
Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL.
Highly Cited
2003
Highly Cited
2003
Exogenous but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved.
Review
2002
Review
2002
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.
Review
2001
Review
2001
Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors.
Review
2001
Review
2001
The ever-emerging anti-inflammatories. Have there been any real advances?
  • K. Rainsford
  • Journal of Physiology - Paris
  • 2001
  • Corpus ID: 21440382
Highly Cited
2000
Highly Cited
2000
Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
AbstractObjective: Prostaglandin synthesis is catalyzed by a constitutive cyclo-oxygenase isoform (COX-1) and an inducible… 
Highly Cited
2000
Highly Cited
2000
A New Cyclooxygenase‐2 Inhibitor, Rofecoxib (VIOXX®), Did Not Alter the Antiplatelet Effects of Low‐Dose Aspirin in Healthy Volunteers
The present study examined whether rofecoxib (VIOXX®), a new specific inhibitor of cyclooxygenase‐2 (COX‐2), would interfere with… 
Review
1999
Review
1999
Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)